These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 10764320

  • 1. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis.
    Cohen AH, Sweet SC, Mendeloff E, Mallory GB, Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR.
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1252-5. PubMed ID: 10764320
    [Abstract] [Full Text] [Related]

  • 2. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL, Kukla A, Thomas D, Wood Ives J, Snyder JJ, Qiu Y, Peng Y, Dharnidharka VR, Israni AK.
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [Abstract] [Full Text] [Related]

  • 3. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE.
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM, Lee SK, Kim SJ, Joh JW, Kwon CH, Choe YH, Shin M, Kim EY, Moon JI, Jung GO, Choi GS.
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis.
    Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R.
    Clin Transplant; 2011 Apr; 25(4):E430-6. PubMed ID: 21518001
    [Abstract] [Full Text] [Related]

  • 6. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.
    Transplantation; 2003 Nov 15; 76(9):1289-93. PubMed ID: 14627905
    [Abstract] [Full Text] [Related]

  • 7. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W, Studies of Pediatric Liver Transplantation Research Group.
    Liver Transpl; 2013 Jul 15; 19(7):730-40. PubMed ID: 23696264
    [Abstract] [Full Text] [Related]

  • 8. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 15; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 9. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Dec 15; 38(6):1755-8. PubMed ID: 16908272
    [Abstract] [Full Text] [Related]

  • 10. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 11. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb 15; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 12. Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients.
    Rosendale B, Yousem SA.
    Arch Pathol Lab Med; 1995 May 15; 119(5):418-23. PubMed ID: 7748068
    [Abstract] [Full Text] [Related]

  • 13. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 14. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 15. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O.
    Transplantation; 2013 Oct 15; 96(7):657-63. PubMed ID: 23823652
    [Abstract] [Full Text] [Related]

  • 16. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 15; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 17. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 15; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 18. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
    Katz BZ, Pahl E, Crawford SE, Kostyk MC, Rodgers S, Seshadri R, Proytcheva M, Pophal S.
    Pediatr Transplant; 2007 Feb 15; 11(1):58-65. PubMed ID: 17239124
    [Abstract] [Full Text] [Related]

  • 19. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
    Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik MA.
    Transplantation; 2009 Oct 15; 88(7):926-34. PubMed ID: 19935465
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.